Bicara Therapeutics (BCAX) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Climb Bio (CLYM) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 440.6% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $539.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | CLYM |
|---|---|---|
| Share price | $8.44 | $9.19 |
| Market cap | $560.31M | $539.80M |
| 1-day change | -7.46% | -0.97% |
| YTD return | -49.85% | +129.75% |
| 1-year return | -53.22% | +440.59% |
| 5-year return | — | -33.21% |
| EPS (TTM) | $-3.46 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-137.95M | $-59.85M |
| 52-week high | $30.99 | $18.33 |
| 52-week low | $7.87 | $1.64 |
| Distance from 52-week high | -72.77% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +281.16% | +209.03% |
| Average volume | 1.20M | 1.38M |
| Shares outstanding | 66.39M | 58.74M |
| Employees | 103 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed BCAX by 493.8 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
BCAX vs CLYM FAQ
Which is bigger, Bicara Therapeutics or Climb Bio?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $539.80M for Climb Bio (CLYM).
Which stock has performed better over the past year, BCAX or CLYM?
CLYM returned +440.59% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Climb Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.